Saturday 17 October 2026
Export DYN’s income statement to Excel — free account
Dyne Therapeutics, Inc.
In the quarter to June 2026, EPS fell 11.3%, free cash flow fell 39.1% and total debt rose 116.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
14.25
1.04
−6.80%
Follow DYN
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | 15.60 | 11.57 | 4.30 | 6.40 | 12.33 | 6.36 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | 27.11 | 32.32 | 15.63 | 15.60 | 47.45 | 26.22 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 47 | 95 | 123 | 141 | 191 | 258 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | — | (5) | (15) | (59) | (149) | (168) | (236) | (317) | (446) | |||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (5) | (15) | (59) | (149) | (168) | (236) | (317) | (446) | |||||
| Depreciation | — | — | 0 | 0 | 1 | 4 | 3 | 1 | (2) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | (0.11) | (6.08) | (4.13) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) | |||||
| Cash flow | — | — | (0.09) | (4.84) | (3.23) | (2.35) | (2.96) | (3.15) | (3.11) | (3.14) | |||||
| Capex | — | — | 0.00 | (0.67) | (0.08) | (0.07) | (0.06) | (0.01) | (0.03) | (0.01) | |||||
| Free cash flow | — | — | (0.09) | (5.52) | (3.31) | (2.42) | (3.02) | (3.16) | (3.13) | (3.15) | |||||
| Book value | — | — | 0.09 | 5.75 | 23.78 | 7.23 | 4.86 | 1.53 | 6.69 | 7.57 | |||||
| Shares, m | — | — | 45 | 2 | 14 | 51 | 52 | 60 | 94 | 128 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | (4) | (12) | (47) | (120) | (154) | (188) | (292) | (403) | ||||
| Capex | — | — | 0 | (2) | (1) | (4) | (3) | (1) | (2) | (2) | |||||
| Free cash flow | — | — | (4) | (13) | (48) | (123) | (157) | (189) | (295) | (405) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | 7 | 12 | 338 | 354 | 238 | 78 | 617 | 1,076 | ||||
| Total debt | — | — | 3 | — | — | 29 | 26 | — | — | 149 | |||||
| Net debt | — | — | (5) | (15) | (345) | (348) | (230) | (123) | (642) | (962) | |||||
| Shareholders’ equity | — | — | 4 | 14 | 342 | 368 | 252 | 91 | 630 | 972 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | (116.38) | (120.30) | (32.15) | (38.33) | (45.93) | (100.10) | (74.14) | (47.52) | ||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | (460.33) | (480.77) | 0.00 | 0.00 | (2,790.00) | |||||
| ROE | — | — | 52.66 | 162.64 | (36.13) | (42.02) | (54.18) | (137.31) | (88.03) | (55.71) | |||||
Negative figures in brackets.
Charts ten years each
Dyne Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| CELC Celcuity, Inc. | $3.0B | — (loss-making) | — | — | n/m | −53.27% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DNLI Denali Therapeutics Inc. | $2.9B | — (loss-making) | — (loss-making) | −89.74% (below 0%: shrinking) | n/m | −22.91% (below 0%: shrinking) | 97.42% | (3,622.11%) | Compare |
| RCUS Arcus Biosciences, Inc. | $2.9B | — (loss-making) | — (loss-making) | −74.38% (below 0%: shrinking) | n/m | +10.53% (above 0%: growing) | 100.00% | (234.15%) | Compare |
| ELVN Enliven Therapeutics, Inc. | $2.9B | — (loss-making) | — | — | n/m | −8.34% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| DYN Dyne Therapeutics, Inc. | $2.9B | — (loss-making) | — | — | n/m | −39.08% (below 0%: shrinking) | 0.00% | 0.00% | |
| NRIX Nurix Therapeutics, Inc. | $2.7B | 9.7× | — (loss-making) | +8,426.27% (above 0%: growing) | n/m | +1,122.10% (above 0%: growing) | 100.00% | 83.12% | Compare |
| ZLAB Zai Lab Limited Unsponsored ADR | $2.7B | — (loss-making) | — (loss-making) | −3.33% (below 0%: shrinking) | n/m | −84.42% (below 0%: shrinking) | 54.70% | (71.95%) | Compare |
| PGEN Precigen, Inc. | $2.6B | — (loss-making) | — (loss-making) | +6,322.66% (above 0%: growing) | n/m | +8.73% (above 0%: growing) | 94.90% | 41.18% | Compare |
| BEAM Beam Therapeutics Inc. | $2.6B | — (loss-making) | — (loss-making) | −94.21% (below 0%: shrinking) | n/m | +13.92% (above 0%: growing) | 100.00% | (25,827.14%) | Compare |
| Median of peers | $2.8B | — | — | −38.85% | — | +0.20% | 96.16% | (35.97%) |
Dyne Therapeutics, Inc. (DYN) key facts
- Dyne Therapeutics, Inc. (DYN) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, DYN traded at $14.25, a market capitalization of $2.9 billion.
- Return on equity was −55.7% and debt-to-equity 0.30.